{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:01:35Z","timestamp":1789732895851,"version":"4.0.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Whether the time-of-day administration (ToDA) of programmed cell death 1 (PD-1) inhibitor infusion influences survival in advanced gastric cancer (AGC) remains unclear. This research aimed to evaluate the impact of ToDA on the prognosis of AGC patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter retrospective study enrolled 416 AGC patients receiving PD-1 inhibitor therapy, who were divided into early and late ToDA groups based on sensitivity analyses using 30-minute intervals of the administration time window. After 1:2 propensity score matching (PSM), progression-free survival (PFS) and overall survival (OS) were compared between groups, and subgroup analyses were conducted. Subsequently, prognostic risk score models were established based on independent prognostic factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A cutoff time of 15:00 was established via sensitivity analyses in the overall cohort. Patients were categorized into early and late ToDA groups. After PSM, multivariable Cox analyses identified late ToDA as an independent risk factor for both PFS (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt;\u00a00.001) and OS (\n                      <jats:italic>P<\/jats:italic>\n                      =\u00a00.004). Kaplan\u2013Meier curves demonstrated significantly better PFS (\n                      <jats:italic>P<\/jats:italic>\n                      =\u00a00.003) and OS (\n                      <jats:italic>P<\/jats:italic>\n                      =\u00a00.003) for the early ToDA group. In the overall cohort, prognostic risk score models incorporating ToDA, metastasis sites, treatment lines, neutrophil-to-lymphocyte ratio (NLR), human epidermal growth factor receptor 2 (HER-2) status and programmed cell death ligand 1 (PD-L1) status effectively stratified patients into low-, middle-, and high-risk groups with distinct survival (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt;\u00a00.001). The detrimental effect was observed across most major subgroups, though several subgroup analyses were not statistically significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This research provides real-world evidence that early ToDA of PD-1 inhibitors is associated with improved prognosis in AGC patients, providing a rationale for chronotherapy optimization and introducing a preliminary risk stratification model for AGC immunotherapy. The risk scoring model requires prospective validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1945065","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:02:47Z","timestamp":1789729367000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Early time-of-day infusion of PD-1 inhibitor improves prognosis in advanced gastric cancer: a multicenter real-world study"],"prefix":"10.3389","volume":"17","author":[{"given":"Ziting","family":"Qu","sequence":"first","affiliation":[{"name":"Department of Oncology, the First Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Oncology, the First Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shupei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, the Second Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Oncology, the Second Affiliated Hospital of Bengbu Medical University","place":["Bengbu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyan","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Oncology, the First Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxi","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Oncology, the First Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]},{"name":"Department of Medicine II, Section Molecular Hepatology, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University","place":["Mannheim, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiyo","family":"Nomura","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, the First Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Oncology, the First Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]},{"name":"Department of Pharmacology, Toxicology and Therapeutics, the University of Kansas Medical Center","place":["Kansas, KS, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21657","article-title":"Current treatment and recent progress in gastric cancer","volume":"71","author":"Joshi","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet (London England)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: The ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"Jama"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005920","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy","volume":"11","author":"Rizvi","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-021909-135821","article-title":"The mammalian circadian timing system: organization and coordination of central and peripheral clocks","volume":"72","author":"Dibner","year":"2010","journal-title":"Annu Rev Physiol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115748","article-title":"Timing of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: A retrospective multicenter study","volume":"228","author":"Tsukaguchi","year":"2025","journal-title":"Eur J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113571","article-title":"Early morning immune checkpoint blockade and overall survival of patients with metastatic cancer: An in-depth chronotherapeutic study","volume":"199","author":"Catozzi","year":"2024","journal-title":"Eur J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb0738","article-title":"Clocks, cancer, and chronochemotherapy","volume":"371","author":"Sancar","year":"2021","journal-title":"Sci (New York NY)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00546-5","article-title":"Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study","volume":"22","author":"Qian","year":"2021","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.01.007","article-title":"Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer","volume":"182","author":"Rousseau","year":"2023","journal-title":"Eur J Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008011","article-title":"Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis","volume":"12","author":"Patel","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251339921","article-title":"Impact of nivolumab monotherapy infusion time-of-day on short- and long-term outcomes in patients with metastatic gastric cancer","volume":"17","author":"Ishizuka","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1653218","article-title":"Overall survival according to time-of-day of combined immuno-chemotherapy for advanced gastric cancer: a propensity score-matched analysis","volume":"16","author":"Cheng","year":"2025","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1614362","article-title":"Health effects of overweight and obesity in 195 countries over 25 years","volume":"377","author":"Afshin","year":"2017","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae197","article-title":"Immune checkpoint inhibitor infusion times and clinical outcomes in patients with melanoma","volume":"30","author":"Fletcher","year":"2025","journal-title":"Oncologist"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102220","article-title":"Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis","volume":"9","author":"Landre","year":"2024","journal-title":"ESMO Open"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70126","article-title":"Overall survival according to time\u2010of\u2010day of immunochemotherapy for extensive\u2010stage small cell lung cancer","volume":"131","author":"Huang","year":"2025","journal-title":"Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.21037\/atm.2018.12.10","article-title":"Balance diagnostics after propensity score matching","volume":"7","author":"Zhang","year":"2019","journal-title":"Ann Transl Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nri3386","article-title":"Circadian control of the immune system","volume":"13","author":"Scheiermann","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1016\/j.cell.2024.04.015","article-title":"Circadian tumor infiltration and function of CD8(+) T cells dictate immunotherapy efficacy","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1905080116","article-title":"The circadian clock of CD8 T cells modulates their early response to vaccination and the rhythmicity of related signaling pathways","volume":"116","author":"Nobis","year":"2019","journal-title":"PNAS"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2214829120","article-title":"Circadian regulator BMAL1::CLOCK promotes cell proliferation in hepatocellular carcinoma by controlling apoptosis and cell cycle","volume":"120","author":"Qu","year":"2023","journal-title":"PNAS"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01859-0","article-title":"Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade","volume":"25","author":"Fortin","year":"2024","journal-title":"Nat Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-24-2083","article-title":"Clocking cancer immunotherapy responses","volume":"84","author":"Wang","year":"2024","journal-title":"Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.Mcr-21-0786","article-title":"Diurnal expression of PD-1 on tumor-associated macrophages underlies the dosing time-dependent antitumor effects of the PD-1\/PD-L1 inhibitor BMS-1 in B16\/BL6 melanoma-bearing mice","volume":"20","author":"Tsuruta","year":"2022","journal-title":"Mol Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41467-021-20935-9","article-title":"Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors","volume":"12","author":"Valero","year":"2021","journal-title":"Nat Commun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.783197","article-title":"The effect of inflammatory markers on the survival of advanced gastric cancer patients who underwent anti-programmed death 1 therapy","volume":"12","author":"Qu","year":"2022","journal-title":"Front Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1945065\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:02:48Z","timestamp":1789729368000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1945065\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2026.1945065"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1945065","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"1945065"}}